See Policy CPT CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

All lines of business

BENEFIT APPLICATION

Medicaid Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

POLICY CRITERIA

Gastrointestinal motility monitoring using a wireless capsule (i.e., SmartPill® GI Monitoring System) is considered investigational and is not covered for all indications.

Link to Policy Summary

CPT CODES

<table>
<thead>
<tr>
<th>All Lines of Business</th>
<th>Not Covered</th>
</tr>
</thead>
<tbody>
<tr>
<td>91112</td>
<td>Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report</td>
</tr>
</tbody>
</table>
DESCRIPTION

Gastroparesis

Gastroparesis is a gastrointestinal motility disorder, not due to an obstruction, where the stomach empties slower than normal causing bloating, nausea, vomiting, and weight loss. The cause of gastroparesis is usually unknown; however, it is common in diabetics and may also be due to certain medications. Gastroparesis can also affect the small and large intestines leading to a diagnosis of irritable bowel syndrome.

Wireless Capsule for Gastrointestinal Motility Monitoring (SmartPill™)

The SmartPill™ Motility Capsule (Medtronic) is part of the SmartPill™ motility testing system. The capsule technology is a self-contained electronic device that wirelessly measures gastrointestinal pH, temperature, and pressure. The patient ingests the capsule and a data receiver nearby collects the data transmitted by the capsule. After data collection, the receiver is returned to the physician for downloading and analysis.

REVIEW OF EVIDENCE

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of a wireless capsule (i.e., SmartPill®) for gastrointestinal motility monitoring. Below is a summary of the available evidence identified through January of 2020.

In 2017, Hayes published a health technology assessment of wireless capsule systems for the diagnosis of gastroparesis and monitoring of gastrointestinal (GI) motility.¹ The technology assessment was last updated in November 2019. The literature review identified 13 nonrandomized studies (3 cross-sectional comparative studies, 7 prospective case-control studies, and 3 retrospective pretest/posttest studies) as eligible for inclusion. Sample sizes ranged from 21 to 196 patients with known or suspected GI motility disorders. Outcome measures included sensitivity, specificity, and accuracy of motility disorder detection.

Although 13 studies were evaluated, “these studies provide limited evidence concerning the accuracy of the wireless capsule systems and no reliable evidence that use of these systems improves patient outcomes.”¹ Five studies evaluated the use of the SmartPill wireless motility capsule (WMC) to detect gastroparesis; however, these studies, “provided limited evidence of the accuracy of WMC.” Six studies reviewed the SmartPill WMC for the detection of delayed colonic transit. Studies compared WMC to conventional techniques (e.g., radiopaque markers), and although agreement between WMC and these techniques was generally good, “the reported measures of test agreement are not precise indicators of the accuracy of WMC relative to conventional testing methods.” Three studies evaluated the clinical utility of WMC testing to improve patient management. Due to their poor quality (retrospective, no follow-up), these studies provided no reliable evidence that information from WMC testing improves patient management.
The overall quality of evidence was determined to be low due to individual study limitations, including lack of randomization, small study size, retrospective analysis, lack of follow-up, and incomplete testing of enrolled patients. The Hayes review concluded that additional studies are needed to determine the accuracy of wireless capsule systems relative to standard testing for the detection of GI motility disorders. “Additional studies are also needed to demonstrate that the information obtained with wireless capsule systems can be used to improve the management and health outcomes of patients who have GI motility disorders.” The following Hayes ratings were assigned for wireless capsule monitors to assess GI motility:

- **C (potential but unproven benefit):** For assessment of gastrointestinal (GI) motility with the SmartPill wireless motility capsule (WMC) system in adult patients without contraindications to use.
- **D2 (insufficient evidence):** For assessment of GI motility with a wireless capsule endoscopy (WCE) system in adult patients without contraindications to use.
- **D2 (insufficient evidence):** For assessment of GI motility with the SmartPill WMC system or a WCE system in pediatric and adolescent patients.

**CLINICAL PRACTICE GUIDELINES**

**National Institute for Health and Care Excellence (NICE)**

The 2014 evidence-based NICE guideline for assessing motility of the gastrointestinal tract using a wireless capsule recommended the following:

“The evidence on assessing motility of the gastrointestinal tract using a wireless capsule raises no major safety concerns. There is evidence of efficacy in measuring gastrointestinal function but uncertainty about the clinical benefit of this, and about patient selection. Therefore, this procedure should be used only with special arrangements for clinical governance, consent and audit or research... NICE encourages further research into the use of a wireless capsule to assess motility of the gastrointestinal tract. Studies should include clear details of patient selection. They should report on the diagnostic accuracy of the procedure in different parts of the gastrointestinal tract, and should provide data on the clinical benefits of the procedure for patients.”

**American College of Gastroenterology (ACG)**

The 2013 ACG evidence-based clinical practice guideline for the management of gastroparesis stated “(a)lternative approaches for assessment of gastric emptying include wireless capsule motility testing and C breath testing using octanoate or spirulina incorporated into a solid meal; they require further validation before they can be considered as alternates to scintigraphy for the diagnosis of gastroparesis. (Conditional recommendation, moderate level of evidence).” The guideline also states “scintigraphic measurement of gastric emptying of solid food is the standard method for diagnosis of gastroparesis.”

In addition to the evidence-based clinical practice guidelines above, four position statements were identified and all conclude a lack of sufficient evidence for wireless gastrointestinal motility capsules.
CEN TERS FOR MEDICARE & MEDICAID

As of 1/17/2020, no Centers for Medicare & Medicaid (CMS) coverage guidance was identified which addresses wireless capsules for gastrointestinal motility monitoring.

POLICY SUMMARY

Although the evidence suggests the wireless motility capsule (i.e., SmartPill) may be useful in diagnosing gastrointestinal (GI) motility disorders, the quality of evidence is low. Additional studies of good methodological quality are required to confirm the clinical validity and clinical utility of wireless capsule GI motility monitoring compared to standard GI motility testing (e.g., gastric emptying study). Furthermore, both the National Institute for Health and Care Excellence and American College of Gastroenterology do not recommend a wireless capsule for gastrointestinal motility monitoring.

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

REGULATORY STATUS

U.S. Food and Drug Administration (FDA)

The SmartPill® GI Monitoring System was approved under the FDA’s 510(k) process as a class II device and assigned the product code NYV. SmartPill cleared 7/2006 (K053547) and version 2.0 cleared 10/2009 (K092343). SmartPill GI Monitoring System is indicated for use in evaluating patients with suspected delayed gastric emptying.

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.
MEDICAL POLICY

MEDICAL POLICY CROSS REFERENCES

- Wireless Capsule Endoscopy, MED376

REFERENCES